TOKYO -- Nikon has opened new bioimaging laboratories in Japan and the U.S., aiming to tap into increased demand for contract pharmaceutical research as it looks to double sales in the field by fiscal 2028 and develop health care into a new pillar of growth.
In January, the company began operations at drug discovery support labs in Fujisawa, Kanagawa prefecture, near Tokyo, and in Lexington, Massachusetts, in the northeast U.S., where medical-related companies are concentrated. The investment is estimated at 1 billion yen ($6.7 million).
